Shares of Evotec SE (NASDAQ:EVO - Get Free Report) traded up 9.4% on Tuesday . The stock traded as high as $4.88 and last traded at $4.88. 37,466 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 139,108 shares. The stock had previously closed at $4.46.
Analysts Set New Price Targets
Several equities analysts recently commented on EVO shares. HC Wainwright restated a "buy" rating and set a $8.00 target price on shares of Evotec in a research report on Thursday, November 7th. Jefferies Financial Group cut Evotec from a "buy" rating to a "hold" rating and cut their price objective for the company from $8.70 to $3.80 in a report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, Evotec has an average rating of "Hold" and an average target price of $5.93.
View Our Latest Analysis on Evotec
Evotec Stock Performance
The stock has a 50-day moving average of $4.40 and a 200 day moving average of $4.13. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43.
Institutional Investors Weigh In On Evotec
A number of hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its position in Evotec by 29.7% in the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock valued at $9,616,000 after buying an additional 602,858 shares during the last quarter. Novo Holdings A S bought a new position in Evotec in the second quarter valued at about $71,183,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Evotec in the second quarter worth about $87,000. DCF Advisers LLC raised its holdings in Evotec by 140.5% during the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock worth $552,000 after purchasing an additional 67,156 shares during the last quarter. Finally, Mediolanum International Funds Ltd bought a new stake in shares of Evotec during the third quarter worth approximately $512,000. Institutional investors own 5.81% of the company's stock.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
See Also
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
